Hologic, IncNasdaq: HOLX
Health Care · Health Care Equipment
$76.03
+0.50%
Vol: 77.5M
Research Digest
Friday, May 1, 2026
Hologic go-private transaction at $79/share closes; Q1 EPS misses estimates
Hologic completed acquisition by Blackstone and TPG at up to $79 per share, establishing company as private. CEO Steve MacMillan retired; José Almeida appointed new CEO. Q1 2026 EPS of $1.04 missed estimates of $1.10 by 5.45%. Revenue increased 2.5% but bottom-line declined 10.9%, falling short of $1.07B forecast. All required regulatory approvals received. Transaction announced Oct 21, 2025 and approved by shareholders Feb 5, 2026. Stock continues trading at $76.01 with bullish technical signals. Upcoming earnings due May 7, 2026. Company develops diagnostics, imaging systems, and surgical products for women's health across Diagnostics, Breast Health, GYN Surgical, and Skeletal Health segments.
Previous Market Intelligence
13 daysApr 30Hologic completes Blackstone/TPG go-private transaction; José Almeida named CEOMixed▶
Hologic announced completion of its go-private transaction with Blackstone and TPG, valued at $18.3 billion. CEO Steve MacMillan retired after 12+ years, during which revenue grew 65% and share price appreciated 241%. José Almeida has been appointed as new CEO. However, Q1 2026 EPS came in at $1.04, missing estimates of $1.10 by 5.45%. The transaction received all required regulatory approvals and shareholder approval with 178.8M votes in favor.
Apr 16Hologic completed Blackstone/TPG acquisition on April 7, 2026 at $76 cash per share plus $3 CVR; delisted from NasdaqNeutral▶
Blackstone and TPG completed acquisition of Hologic on April 7, 2026, with shareholders receiving $76 cash per share plus non-tradable contingent value rights worth up to $3 per share tied to Breast Health revenue targets. Long-time CEO Steve MacMillan retired immediately upon close, replaced by Jose E. Almeida. Nasdaq filed delisting and deregistration on April 7, ending public trading. This is no longer an actively traded public company.
Apr 15Hologic completed Blackstone-TPG acquisition on April 7; delisted from Nasdaq and taken private.Neutral▶
On April 7, 2026, Hologic completed its $18.3B acquisition by funds managed by Blackstone and TPG. Shareholders received $76 per share in cash plus contingent value rights up to $3/share if revenue targets are met. The stock delisted from Nasdaq and ceased public trading. On April 6, CEO Steve MacMillan retired and Jose E. Almeida was appointed as new CEO. No longer a public stock post-acquisition close.
Apr 14Hologic delisted after Blackstone-TPG acquisition completion at up to $79 per share; new CEO Joe Almeida appointed.Neutral▶
Blackstone and TPG completed acquisition of Hologic on April 7, 2026 at $76 cash per share plus contingent value right up to $3 per share based on Breast Health revenue milestones in FY 2026-2027. Stock has delisted from Nasdaq. Joe Almeida appointed as new CEO replacing Steve MacMillan who retired. Deal includes significant minority investments from Abu Dhabi Investment Authority and GIC.
Apr 13Hologic completed Blackstone-TPG acquisition on April 7 at $76 cash plus CVR, delisting from NASDAQ.Neutral▶
Hologic completed go-private acquisition by Blackstone and TPG on April 7, 2026. Stockholders received $76 per share cash plus non-tradable CVR worth up to $3 per share, valuing transaction at $17.3-18.3 billion. NASDAQ suspended trading and delisted the company on April 7.
Apr 10Hologic taken private by Blackstone and TPG for $79/share, delisted from S&P 500 on April 9; CEO retiring.Neutral▶
Blackstone and TPG completed their acquisition of Hologic on April 7, 2026, taking the women's health company private at $76 cash per share plus contingent value rights of up to $3 per share. CEO Stephen MacMillan announced retirement effective immediately, with Jose Almeida appointed as new CEO. Hologic was delisted and replaced in the S&P 500 by Casey's General Stores.
Apr 9Hologic acquisition closes at $79/share; CEO MacMillan retires, Almeida appointedNeutral▶
Blackstone and TPG completed Hologic acquisition April 6, 2026 at $76/share cash plus $3/share CVR (up to $79/share total) pending Breast Health revenue goals FY2026-2027. Hologic delisted from Nasdaq (last trading day April 6). Long-time CEO Steve MacMillan retired immediately; José (Joe) E. Almeida appointed new CEO effective immediately. Stock closed $76.01 (+0.48%) on 102M+ shares at offer price. Transaction announced October 21, 2025; shareholder vote approved February 5, 2026. Now private company under PE ownership. No longer publicly traded as of April 8.
Apr 8Hologic acquisition by Blackstone and TPG completed April 7 at $79 per shareNeutral▶
Hologic completed go-private acquisition April 7 by Blackstone and TPG at $79/share with ADIA and GIC as minority investors. José Almeida appointed CEO, Steve MacMillan retiring. Stock delisted from Nasdaq. Company now wholly private.
Apr 7No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Apr 6Hologic shareholders approved Blackstone/TPG buyout at up to $79/share.Positive▶
Hologic shareholders approved acquisition by Blackstone and TPG funds in February 2026. Deal: $76/share cash plus up to $3 contingent value right for $79/share total. Enterprise value $18.3B. Expected close H1 2026. Q1 2026 EPS $1.04 missed estimate of $1.10.
Apr 3Hologic shareholders overwhelmingly approved Blackstone/TPG merger at $79 per share with expected closing in March/April 2026.Mixed▶
Hologic shareholders approved the merger with Blackstone and TPG affiliates valued at $79 per share, though advisory executive pay vote was rejected. Stock closed April 2 at $75.65 with 35% surge in trading volume. Recent quarterly results missed expectations with $1.04 EPS versus $1.09 forecast.
Apr 2Hologic pending acquisition by Blackstone and TPG for up to $79 per share remains on track; Q1 2026 EPS of $1.04 missed $1.10 estimate.Mixed▶
Hologic is being acquired by Blackstone and TPG funds at up to $79 per share (enterprise value ~$18.3B). Shareholders receive $76 in cash per share plus contingent value right up to $3 per share based on Breast Health revenue goals for fiscal 2026-2027. Shareholders approved deal on February 4, 2026. Q1 2026 EPS of $1.04 missed $1.10 estimate by 5.45%. FDA approved Aptima HPV Assay for HPV primary screening on February 3.
Apr 1Hologic to be acquired by Blackstone and TPG for up to $79 per share, representing 46% premium.Positive▶
Hologic announced a definitive acquisition agreement valued at up to $79 per share, with funds managed by Blackstone and TPG acquiring all outstanding shares for $76 in cash plus a CVR of up to $3 per share. The aggregate enterprise value is up to $18.3 billion.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| HOLXHOLOGIC | $76.03 | +0.50% | +0.0% | 15.7x | 0.70 | $17.0B |
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.